Swiss National Bank Purchases 1,200 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Swiss National Bank increased its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 1.1% during the 4th quarter, Holdings Channel reports. The firm owned 115,200 shares of the company’s stock after acquiring an additional 1,200 shares during the period. Swiss National Bank’s holdings in Twist Bioscience were worth $5,353,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the 3rd quarter valued at approximately $34,000. Van ECK Associates Corp grew its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. US Bancorp DE increased its holdings in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience in the 3rd quarter worth $95,000. Finally, KBC Group NV boosted its holdings in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter.

Twist Bioscience Price Performance

TWST stock opened at $44.94 on Tuesday. The stock has a market cap of $2.68 billion, a PE ratio of -13.30 and a beta of 2.15. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a 50-day moving average price of $45.42 and a 200 day moving average price of $45.31. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) earnings per share. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on TWST. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares in the company, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 5,200 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the sale, the chief executive officer now owns 667,318 shares of the company’s stock, valued at approximately $32,932,143.30. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,799 shares of company stock valued at $1,593,944 in the last quarter. 3.01% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.